Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...1415161718192021222324...123124»
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Systemic therapy of hepatocellular carcinoma on non-cirrhotic liver: a prospective spanish multicentre study (Poster Area) -  Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1063;    
    In our series, patients with HCC on non-cirrhotic liver required more frequently ST due to tumour progression/recurrence after previous treatments than initial therapy for advanced disease. Survival was similar and safety profile was slightly better than clinical trials data, being severe AE uncommon reason for discontinuation.
  • ||||||||||  Networks in focus: profile of immune-related adverse events in first-line immunotherapy for hepatocellular carcinoma (Poster Area) -  Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1062;    
    The median time to the first adverse event that required treatment interruption was 64 days, and in 12.8% of the patients, this adverse event occurred after the first dose of immunotherapy. This data emphasizes the importance of establishing hospital networks for early detection and management of immune-related adverse events, ensuring timely access to experienced specialists.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Efficacy and safety of neoadjuvant therapy in narrow-margin hepatocellular carcinoma: a propensity score matching analysis (Poster Area) -  Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1036;    
    NAT is defined as preoperative treatment, which includes local therapy (radiotherapy or interventional therapy) alone, or local therapy plus systemic therapy (PD-1 inhibitor + lenvatinib)... Patients with narrow-margin HCC who received NAT combined with surgery had a better prognosis and showed an acceptable safety profile than those who received surgery alone.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metabolomic study:  Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy. (Pubmed Central) -  Apr 1, 2024   
    Proteomic analysis of cancer tissues unveils molecular features that are associated with side effects in responders receiving combination therapy. In conclusion, our analysis identifies plasma features associated with uHCC responders to combination therapy.
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open:  Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) -  Apr 1, 2024   
    P2,  N=30, Recruiting, 
    In conclusion, our analysis identifies plasma features associated with uHCC responders to combination therapy. Not yet recruiting --> Recruiting
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date:  Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors (clinicaltrials.gov) -  Mar 26, 2024   
    P2,  N=20, Active, not recruiting, 
    IO-TKI therapy exhibited superior effectiveness over IO-IO therapy in terms of PFS improvement and immediate disease progression prevention and was associated with a higher risk of treatment interruption and a lower risk of needing corticosteroids. Trial completion date: Jan 2024 --> Jul 2024
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    P4 data, Journal, Adverse events:  Novel insights into post-marketing adverse events associated with lenvatinib: A comprehensive analysis utilizing the FAERS database. (Pubmed Central) -  Mar 25, 2024   
    This study has successfully detected novel and unforeseen signals pertaining to ADRs associated with the administration of lenvatinib, thereby contributing significant insights into the intricate correlation between ADRs and the utilization of lenvatinib. The outcomes of this investigation underscore the utmost significance of continuous monitoring and vigilant surveillance in order to promptly identify and effectively manage AEs, consequently enhancing overall patient safety and well-being in the context of lenvatinib therapy.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  SiRNA-HIF-1? delivered by attenuated Salmonella enhances the efficacy of Lenvatinib against hepatocellular carcinoma. (Pubmed Central) -  Mar 25, 2024   
    This treatment approach reduced cell proliferation and angiogenesis in HCC tissues while promoting tumor cell apoptosis. Additionally, this combined therapy significantly increased the infiltration of T lymphocytes and M1 macrophages within the tumor microenvironment, as well as elevated the proportion of immune cells in the spleen, thereby potentiating the host's immune response against the tumor.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  A case of hepatocellular carcinoma with pseudoaneurysm formation upon lenvatinib administration. (Pubmed Central) -  Mar 25, 2024   
    Lenvatinib demonstrated effectiveness in inhibiting angiogenesis in the tumor, as evidenced by a decrease in tumor blood flow. This case report suggests that pseudoaneurysm formation within the tumor occurs early after the administration of lenvatinib; thus, clinicians must be aware of the potential risk of pseudoaneurysm rupture.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion, Enrollment change:  A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients (clinicaltrials.gov) -  Mar 25, 2024   
    P=N/A,  N=135, Completed, 
    This case report suggests that pseudoaneurysm formation within the tumor occurs early after the administration of lenvatinib; thus, clinicians must be aware of the potential risk of pseudoaneurysm rupture. Recruiting --> Completed | N=98 --> 135
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Acute Interstitial Nephritis Secondary to Pembrolizumab () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_559;    
    IrAEs are increasing in frequency with more adoption of ICPis. Physicians should consider AIN in patients who develop acute kidney injury with current or recent use of ICPis, and medications that may predispose to AIN such as proton pump inhibitors should be held.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Journal:  Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab. (Pubmed Central) -  Mar 22, 2024   
    Physicians should consider AIN in patients who develop acute kidney injury with current or recent use of ICPis, and medications that may predispose to AIN such as proton pump inhibitors should be held. Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib.
  • ||||||||||  erfonrilimab (KN046) / Alphamab, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion, Trial completion date, Combination therapy, Metastases:  The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Mar 21, 2024   
    P2,  N=55, Completed, 
    Our results confirm the effectiveness of lenvatinib in the management of patients with advanced DTC and support the need to adjust the dosage of lenvatinib to patient Recruiting --> Completed | Trial completion date: May 2023 --> Mar 2024
  • ||||||||||  Opdivo (nivolumab) / BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed:  Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) (clinicaltrials.gov) -  Mar 21, 2024   
    P2,  N=51, Active, not recruiting, 
    Recruiting --> Completed | Trial completion date: May 2023 --> Mar 2024 Recruiting --> Active, not recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma. (Pubmed Central) -  Mar 18, 2024   
    Using a small-molecule specific inhibitor ICG001 and knocking down LEF1 showed that targeting LEF1 restored the sensitivity of LR HCC cells to lenvatinib. Our results uncover upregulation of LEF1 confers lenvatinib resistance by facilitating EMT, cell migration, and invasion of LR HCC cells, indicating that LEF1 is a novel therapeutic target for overcoming acquired lenvatinib resistance.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial initiation date, Trial primary completion date:  Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma (clinicaltrials.gov) -  Mar 15, 2024   
    P2,  N=56, Not yet recruiting, 
    In future studies, more basic experiments and clinical explorations are needed to enhance the effects of TKIs in the treatment of patients with ATC. Trial completion date: Dec 2028 --> Jun 2029 | Initiation date: Jan 2024 --> May 2024 | Trial primary completion date: Dec 2026 --> Jun 2029
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    IMMUNOTHERAPY VERSUS LENVATINIB IN ADVANCED HEPATOCELLULAR CARCINOMA: A MULTICENTER, NATIONWIDE PROPENSITY SCORE MATCHING ANALYSIS (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_7942;    
    When stratified by HCC etiology, there was a survival advantage with immunotherapy in patients with viral hepatitis (HR 0.70, 95%CI 0.51-0.94, log-rank p=0.01) and MASLD/MASH (HR 0.60, 95%CI 0.39-0.93, log-rank p=0.02) but not in patients with alcohol-associated liver disease (HR 0.76, 95%CI 0.47-1.20, p=0.27) or other etiology (HR 1.20, 95%CI 0.89-1.58, p=0.24). Conclusions Our study suggests that immunotherapy is associated with better survival compared to lenvatinib for patients with advanced HCC including patients with MASLD-related HCC.